retatrutide weight loss clinical trial results just delivered one of the largest weight-loss signals we've ever seen in a medication trial. In a phase 2 study: • Up to 24.2% mean at 48 weeks Retatrutide, a TRIPLE agonist (GLP1,

Furthermore, the Food and Drug Administration has warned that some supplements marketed for controlling blood sugar may contain unapproved ingredients and may not work as promised

GLP-1 receptor agonists and dementia outcomes: A meta-analysis of randomized trials

We propose that GLP-1 analogs are superior to DPP-4 inhibitors for managing pasireotide-induced hyperglycemia because GLP-1 analogs, unlike DPP-4 inhibitors, spare pasireotide-induced depletion of endogenous GLP-1 and restore insulin secretion suppressed by pasireotide through GLP-1R-Gs activation, counteracting the SSTRs-Gi axis

Regular and gentle physical activity Light, regular movement like walking, stretching, or yoga can help your digestion work better and prevent gas from building up

Your weight loss success depends on finding a regimen you can actually stick to, not just the one that looks best on paper

Lowers rates of non-fatal myocardial infarction, non-fatal stroke, and cardiovascular death